COVID-19 and steatotic liver disease in overweight and obese children: comorbidity or negative consequences?
DOI:
https://doi.org/10.32782/2077-6594/2024.2/11Keywords:
metabolic-associated steatosis of the liver, MASLD, SARS-CoV-2, COVID-19Abstract
Goal of research: To investigate the peculiarities of the course of COVID-19 in children with existing metabolic disorders. Materials and methods. Two groups of children diagnosed with SARS-CoV-2 infection participated in the study, divided according to the criterion of the presence and absence of signs of metabolic disorders. Results. It was found that SARS-CoV-2 infection has a systemic negative effect on the body of children and adolescents. Due to the simultaneous involvement of several pathogenetic mechanisms, pathogens lead to noticeable pathological changes in the metabolic profile of children and adolescents with COVID-19. A regularity is observed, according to which in children and adolescents with already existing metabolic disorders and/or diffuse liver diseases, the disease due to COVID-19 has a more severe course and leads to significant clinical and laboratory disturbances on the part of various links of metabolism. Conclusions. The presence of metabolic disorders and/or diffuse liver diseases should be considered as a risk factor for the severe course of COVID-19. At the same time, active SARS-CoV-2 infection in such patients probably leads to rapid progression of metabolic changes.
References
Nicastro E, Ebel N.H, Kehar M, Czubkowski P, Michaels M.G, Lobritto S.J, Martinez M, Indolfi G. The Impact of Severe Acute Respiratory Syndrome Coronavirus Type 2 on Children With Liver Diseases: A Joint European Society for Pediatric Gastroenterology, Hepatology and Nutrition and Society of Pediatric Liver Transplantation Position Paper. J Pediatr Gastroenterol Nutr. 2022; № 74(1): P.159–170. doi: 10.1097/MPG.0000000000003339. PMID: 34694269; PMCID: PMC8673661.
Kehar M, Ebel N.H, Ng V.L, Baquero JER, Leung D.H, Slowik V, Ovchinsky N, Shah A.A, Arnon R, Miloh T, Gupta N, Mohammad S, Kogan-Liberman D, Squires J.E, Sanchez M.C, Hildreth A, Book L, Chu C, Alrabadi L, Azzam R, Chepuri B, Elisofon S, Falik R, Gallagher L, Kader H, Mogul D, Mujawar Q, Namjoshi S.S, Valentino P.L, Vitola B, Waheed N, Zheng M.H, Lobritto S, Martinez M. Severe Acute Respiratory Syndrome Coronavirus-2 Infection in Children With Liver Transplant and Native Liver Disease: An International Observational Registry Study. J Pediatr Gastroenterol Nutr. 2021; № 72(6): Р. 807–814. doi: 10.1097/MPG.0000000000003077. PMID: 33605666; PMCID: PMC8183254.
Slusher A.L, Hu P, Samuels S, Tokoglu F, Lat J, Li Z, Alguard M, Strober J, Vatner D, Shabanova V, Caprio S. Rising NAFLD and metabolic severity during the Sars-CoV–2 pandemic among children with obesity in the United States. Obesity (Silver Spring). 2023; №31(5): Р. 1383–1391. doi: 10.1002/oby.23728. PMID: 36694381; PMCID: PMC10186584.
Fontana L, Eagon J.C, Trujillo M.E, Scherer P.E, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007; № 56(4): Р. 1010–3. doi: 10.2337/db06–1656. Epub 2007 Feb 7. PMID: 17287468.
Nagata J.M, Yang J, Alsamman S, Al-Shoaibi A.A.A, Ganson K.T, Pettee Gabriel K, Baker F.C. Higher blood pressure and weight observed among early adolescents during the COVID-19 pandemic. Am J Prev Cardiol. 2023; №14: Р.100508. doi: 10.1016/j.ajpc.2023.100508. Epub 2023 May 20. PMID: 37313357; PMCID: PMC10198794.
Lee S.J, Kim Y.R, Lee Y.H, Yoon K.H. US Attenuation Imaging for the Evaluation and Diagnosis of Fatty Liver Disease. J Korean Soc Radiol. 2023; № 84(3): Р. 666–675. doi: 10.3348/jksr.2022.0053. Epub 2023 May 18. PMID: 37324990; PMCID: PMC10265227.
Ting Y.W, Wong S.W, Anuar Zaini A, Mohamed R, Jalaludin M.Y. Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease. Front Pediatr. 2019; № 7: Р. 491. doi: 10.3389/fped.2019.00491. PMID: 31850288; PMCID: PMC6901954.
Hayat U, Ashfaq M.Z, Johnson L, Ford R, Wuthnow C, Kadado K, El Jurdi K, Okut H, Kilgore W.R, Assi M, Siddiqui A.A. The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis. Kans J Med. 2022; №15: Р. 241–246. doi: 10.17161/kjm.vol15.16522. PMID: 35899064; PMCID: PMC9311786.
Xu Y, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids Health Dis. 2021; № 20(1): Р. 126. doi: 10.1186/s12944–021–01564-z. PMID: 34602072; PMCID: PMC8487451.
Bitar R, Elghoudi A.A, Rawat D, Azaz A, Miqdady M, Narchi H. COVID-19-induced liver injury in infants, children, and adolescents. World J Clin Pediatr. 2023; № 12(3): Р. 57–67. doi: 10.5409/wjcp.v12.i3.57. PMID: 37342451; PMCID: PMC10278079.
Boettler T, Marjot T, Newsome P.N, Mondelli M.U, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020; № 2(5): Р.100169. doi: 10.1016/j.jhepr.2020.100169. Epub 2020 Aug 4. PMID: 32835190; PMCID: PMC7402276.
